Allergan poised to reject Valeant’s $46bn bid

[at Financial Times] – Allergan, the maker of Botox, is preparing to reject the $46bn offer by rival Valeant Pharmaceuticals, setting up the prospect of a hostile takeover battle at the top of the US drug-making industry. Allergan, … more

View todays social media effects on VRX

View the latest stocks trending across Twitter. Click to view dashboard

See who Valeant is hiring next, click here to view